The oncostatic and immunosuppressive action of new nitrosourea derivatives containing sugar radicals.
Four new nitrosourea derivatives represent an appreciable progress in the treatment and cure of L1210 leukemia. Their therapeutic index is higher than that of CCNU and MeCCNU. Of these compounds, RFCNU may prove the most promising, as its therapeutic index is the highest of those for all the four compounds studied; moreover, unlike the other products, it is not immunosuppressive, whether administered before or after the antigen.
D000818:Animals; D000970:Antineoplastic Agents; D004353:Drug Evaluation, Preclinical; D005947:Glucose; D007165:Immunosuppression Therapy; D007939:Leukemia L1210 / Q000188:drug therapy; D051379:Mice; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D012266:Ribose; D014994:Xylose
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D012266:Ribose; D014994:Xylose; D005947:Glucose